HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Absolute lymphocyte count predicts therapeutic efficacy and survival at the time of radioimmunotherapy in patients with relapsed follicular lymphomas.

AuthorsL F Porrata, K Ristow, T E Witzig, N Tuinistra, T M Habermann, D J Inwards, S M Ansell, I N Micallef, P B Johnston, S N Markovic
JournalLeukemia (Leukemia) Vol. 21 Issue 12 Pg. 2554-6 (Dec 2007) ISSN: 1476-5551 [Electronic] England
PMID17581607 (Publication Type: Letter, Research Support, N.I.H., Extramural)
Chemical References
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Yttrium Radioisotopes
  • Rituximab
  • ibritumomab tiuxetan
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal (therapeutic use)
  • Antibodies, Monoclonal, Murine-Derived
  • Disease-Free Survival
  • Drug Resistance, Neoplasm
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphocyte Count
  • Lymphoma, Follicular (blood, mortality, radiotherapy)
  • Male
  • Middle Aged
  • Prognosis
  • Radioimmunotherapy
  • Recurrence
  • Rituximab
  • Salvage Therapy
  • Survival Analysis
  • Yttrium Radioisotopes (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: